MIH
NBIX icon

Meitav Investment House’s Neurocrine Biosciences NBIX Stock Holding History

Meitav Investment House’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,000
Closed -$1.84M – 244
2025
Q4 		$1.84M Buy
+13,000
New +$1.88M 0.02% 141
2024
Q2 		– Sell
-5,750
Closed -$793K – 232
2024
Q1 		$793K Buy
+5,750
New +$785K 0.02% 152

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Meitav Investment House's NBIX Position: Q1 2026 in Review

Meitav Investment House sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 13,000 shares — an estimated $1.84M sold.

Meitav Investment House first reported a position in NBIX in Q1 2024 and held it in 2 quarters. The position peaked at $1.84M in Q4 2025. 696 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Meitav Investment House reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • Meitav Investment House sold 13,000 Neurocrine Biosciences shares in Q1 2026, an estimated $1.84M.
  • Meitav Investment House first reported a position in Neurocrine Biosciences in Q1 2024 and held it in 2 quarters.
  • Meitav Investment House's Neurocrine Biosciences position peaked at $1.84M in Q4 2025.
  • 696 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Meitav Investment House's 13F filing for Q1 2026, filed 29 Apr 2026.